Wayne State University

Transtarget, Inc.

University of Virginia Patent Foundation

The Medical College of Wisconsin, Inc.

University of Pennsylvania

Roger Williams Hospital

Roger Williams Medical Center

Lawrence G Lum

Archana Thakur

Manley Huang

Carl H June

Michael C Milone

Yangbing Zhao

Jeffrey A Medin

Robyn A A Oldham

Randall J Lee

Robert Blake Hill

Kaothara Oluwakemi Adeyanju

Gerald Elfenbein

Gerlad Elfenbein

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies

The present invention provides methods for inducing and expanding anti-tumor immunity leading to enhanced clinical and immunotherapeutic responses. The invention also provides novel compositions and methods for the treatment of cancer.

Methods and compositions for vaccinating and boosting cancer patients

The present disclosure provides soluble truncated mutant programmed death-ligand 1 (PD-L1) peptides. Polynucleotides and vectors encoding the soluble truncated mutant PD-L1 peptides are also provided. Further, methods of using the soluble truncated mutant peptides to promote differentiation of CD4+ effector T (Th1) cells into Foxp3+ regulatory T (Treg) cells are provided.

Recombinant PD-L1 peptides and methods of use

The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Methods and compositions for cells expressing a chimeric intracellular signaling molecule

CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies

The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an intracellular signaling molecule in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.

Polyclonal bispecific antibody compositions and method of use

The arming of activated T cells (ATC) with BiAbs can overcome major barriers for successful adoptive immunotherapy. The BiAb approach takes the advantage of the targeting specificity of monoclonal antibodies and the cytotoxic capacity of T cells to lyse tumors. Arming of ATC with BiAb makes every T cell an antigen-specific CTL and infusions of such cells will markedly increase the effective precursor frequency of CTL in the cancer patient. Furthermore, the ability of such armed ATC to kill multiple times without rearming with BiAb, secrete tumoricidal cytokines, secrete chemokines, and survive in patients for up to 8 days after the last infusion or in Beige/SCID mice for over 13 weeks after cessation of treatment. The persistence of cells in the Beige/SCID after infusion show long-term survival capability in the host. Re-stimulation of armed ATC after 3 cycles of cytotoxicity with tumor cells resulted in the secretion of interferon gamma indicating the development of tumor specific immune responses in the population of cells that have been exposed multiple times to antigen. In summary, armed ATC can act as a cytotoxic 'drug', kill multiple times (direct killing), divide after killing (increasing the effector:target ratio in vivo), secrete tumoricidal cytokines (indirectly killing), secrete chemokines at the tumor site (recruit na&#xef;ve T cells and antigen-presenting cells to immunize the patient to tumor lysate) and persist in patients and animal models for weeks to months (long-term survival).

In situ immunization

This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits.

Growing community of inventors

Harrison Township, MI, United States of America

Lawrence G Lum